All Brands Owned by Microbix Biosystems Inc.

What does Microbix Biosystems do?
Microbix Biosystems manufactures biological products for the global diagnostics industry. The company produces antigens used by approximately 100 diagnostics manufacturers to develop infectious disease antibody tests, and quality assessment products (QAPs) that help clinical laboratories verify test accuracy. Microbix also develops Kinlytic urokinase, a biologic thrombolytic drug for dissolving blood clots.

Is Microbix Biosystems publicly traded?
Yes, Microbix Biosystems trades on the Toronto Stock Exchange under ticker MBX. The company also trades on the OTCQX Best Market in the United States under the symbol MBXBF. Microbix went public in 1992 and is headquartered in Mississauga, Ontario, Canada.

Who founded Microbix Biosystems?
Microbix was founded in 1984 by William J. (Bill) Gastle, a virologist who started the company with the sale of bacterial and cellular growth media to Canadian public health laboratories. Gastle led the company until his passing on September 6, 2023, in Edmonton, Alberta. He built Microbix from a small laboratory media supplier into a global life sciences company.

What is Kinlytic urokinase?
Kinlytic is Microbix's brand of urokinase, a biologic thrombolytic drug that dissolves blood clots. It was previously marketed in the United States as Abbokinase for over 20 years. Microbix signed an agreement in May 2023 with Sequel Pharma LLC to fund the return of Kinlytic to the US market, with approximately C$50 million in funding needed for relaunch. FDA re-approval is anticipated in approximately two to three years from 2023.

What were Microbix's FY2025 financial results?
Microbix reported FY2025 (fiscal year ended September 30, 2025) revenue of C$18.6 million, a 27% decrease from FY2024 revenue of C$25.4 million. The company recorded a net loss of C$2.2 million, compared to net income of C$3.5 million in FY2024. The decline resulted from reduced antigen sales to China, cancellation of a QAPs client program, and absence of Kinlytic license payments.

What is Microbix's relationship with Sequel Pharma?
Microbix signed a commercialization agreement with Sequel Pharma LLC in May 2023 to return Kinlytic urokinase to the US market. Sequel, funded by a private equity firm, provides the estimated C$50 million needed for FDA re-approval and relaunch. Microbix has received US$4.0 million from Sequel and expects further milestone and royalty payments following FDA re-approval.

How is Microbix recovering from its FY2025 setbacks?
In Q3 FY2026 (quarter ended June 30, 2026), Microbix reported 17% year-over-year sales growth, driven by gains in its antigen and quality assessment product businesses. Excluding its Chinese distributor, antigen sales increased 6% in H1 FY2026. The company is working to add new client programs and clients to diversify its revenue base and reduce concentration risk.